AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05174507 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: saline subcutaneous (s.c.) (placebo)
Description: Placebo for anakinra is 0.67 ml of sterile 0.9 % saline solution s. c. Treatment consists of a single subcutaneous injection of matched placebo (0.67 ml of 0.9 % saline) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
Study NCT05174507 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: tablet per oral (p.o.) (placebo)
Description: Placebo for empagliflozin is Winthrop P® (Zentiva, Frankfurt/Main) lactose tablet. Treatment consists of a single oral tablet of matched placebo two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
Study NCT05550064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured contraceptive counseling
Description: 1. Educational video - healthcare providers (Medical doctors and nurse-midwives)present available contraceptives that could be used after delivery, with emphasis on effectiveness, how they should be used, mechanism of action and health benefits.~2. The four key questions are to be asked to all pregnant women to make them reflect on factors that highly affects choice of contraceptives.~3. A tiered effectiveness chart will be used to visualize the effectiveness of different contraceptives, and guide the prospective user in her choice depending on the answers to the key questions~4. The box of contraceptive models are used for the prospective user to inspect, hold, feel the different contraceptives, as this has been shown to decrease fear regarding specific methods.
Study NCT04472208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring solution
Description: Subjects participating in this study will be monitored with the site's standard of care primary monitor and the evaluable device as the secondary monitor.
Study NCT04847115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative
Description: Intramedullary screw fixation
Study NCT04847115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking boot orthosis
Description: Non-operative treatment with walking boot orthosis for six weeks. The non-operative study arm will use walking boot orthosis only. The operative study arm will use walking boot orthosis as adjuvant treatment.
Study NCT06511154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation
Description: Cognitive rehabilitation is a treatment method used to regain or improve cognitive abilities.For the cognitive rehabilitation program, the Daily Exercise Package of the Norosoft Program, which mainly includes exercises to improve attention, information processing speed, verbal and visual memory functions, will be applied.~Core-based Upper Extremity Exercises~Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises
Study NCT06511154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core-based Upper Extremity Exercises
Description: Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises
Study NCT06511154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core-based Upper Extremity Exercises
Description: Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises
Study NCT04820829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High RM, low NSS
Description: Participants in this group will consume nine 3-oz-eq servings of RM per week and 2-oz-eq servings of NSS per week.
Study NCT06434779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JETi 6F and 8F Thrombectomy system
Description: To demonstrate the efficacy and safety of the mechanical thrombectomy device (JETi 6F and 8F) for treatment of patients with symptomatic peripheral artery disease (PAD) due to acute or acute on chronic occlusions of the femoral and/or popliteal arteries and the first 10 cm of the below-the -knee arteries.
Study NCT06476821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986435
Description: Specified dose on specified days
Study NCT06202079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR4 Injection
Description: GZR4 injection s.c., once-weekly, treat-to-target dose
Study NCT06202079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Insulin Degludec s.c., once-daily, treat-to-target dose
Study NCT05094336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: AMG 193: Orally via tablet
Study NCT05094336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: Intravenous infusion
Study NCT05094336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator AMG 193 Test Tablet
Description: Comparator AMG 193 test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: AMG 193 Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator AMG 193 test tablet.
Study NCT06410248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06410248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06410248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06410248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study NCT06410248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT04820829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate RM, Moderate NSS
Description: Participants in this group will consume five 3-oz-eq servings of RM per week and 5-oz-eq servings of NSS per week.
Study NCT05055336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastric emptying breath test
Description: The gastric emptying breath test is used to diagnose gastroparesis. Participants ingest spirulina in a meal and samples are taken every 45 minutes for 4 hours.
Study NCT05055336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stomach ultrasound
Description: Ultrasound of the fundus of the stomach will be done immediately after ingestion of the test meal, at 15 minutes, and at 30 minutes.
Study NCT06410248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triapine
Description: Given PO
Study NCT04820829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low RM, High NSS
Description: Participants in this group will consume one 3-oz-eq serving of RM per week and 8-oz-eq servings of NSS per week.
Study NCT05014958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training on whole body vibration
Description: Participants will be included in the 6-week exercise training on whole body vibration
Study NCT05014958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training on whole body vibration
Description: Participants will be included in the 6-week exercise training on whole body vibration
Study NCT05413096 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination of diclofenac potassium and propolis
Description: Patients will be divided into two groups: the first one will be treated with a combination of diclofenac 3% (10 mg/g, 60 g, EMS) and Propolis 5% gel and the second one is placebo group. Participants will be allocated randomly. The patients will be asked to apply gel 2 times per day. The patients will be instructed, not to eat or drink for 1 h after application of the gel
Study NCT05413096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT06275620 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGTC-501 (high dose and standard corticosteroid regimen)
Description: Adeno-associated virus vector expressing a human RPGR gene
Study NCT06275620 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGTC-501 (low dose and standard corticosteroid regimen)
Description: Adeno-associated virus vector expressing a human RPGR gene
Study NCT06275620 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGTC-501 (high dose and modified corticosteroid regimen)
Description: Adeno-associated virus vector expressing a human RPGR gene
Study NCT05747534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larazotide Acetate
Description: AT1001 (Larazotide) is a locally acting, non-systemic, octapeptide inhibitor of the zonulin receptor that has shown efficacy in a large variety of animal models of inflammation. The effectiveness of AT1001 in controlling paracellular permeability as a tight junction regulator has been widely demonstrated in animal models both in vitro and in vivo. In MIS-C, prolonged presence of SARS-CoV-2 in the GI tract leads to release of zonulin, a biomarker of intestinal permeability, with subsequent trafficking of SARS-CoV-2 antigens into the bloodstream, leading to hyperinflammation (Yonker, et. al. 2021). Five children treated with AT1001 (through an Emergency Investigational New Drug request authorized by the FDA) displayed a decrease in plasma SARS-CoV-2 Spike antigen levels, inflammatory markers, and symptom improvement superior to that achieved with the current standard of treatment for MIS-C (ie. immunoglobulin, systemic steroids) (Yonker, et. al. 2021) (Yonker, et. al. 2022)
Study NCT05747534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally four times a day (QID) to participants in the placebo arm.
Study NCT05133700 — intervention group
Intervention type: OTHER
Intervention: Interview or focus group discussion
Description: There is no intervention. This is a qualitative piece of work only
Study NCT05133700 — intervention group
Intervention type: OTHER
Intervention: Review of submitted medicines audit tools
Description: There is no intervention. This is a qualitative piece of work only
Study NCT05646823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic blend
Description: Bifidobacterium longum CCT 1934; Bifidobacterium lactis CCT 7858; Lactobacillus rhamnosus CCT 7863; Streptococcus thermophilus ATCC 19258) Final concentration: 1 x 10e10 CFU/ day
Study NCT05646823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle only - Maltodextrin gluten free
Study NCT05374785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL409116
Description: CPL409116 contained in the tablet called PG242 (60 mg)
Study NCT05374785 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets without CPL409116 as an active substance
Study NCT06269263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Description: Guided by physiotherapists, patients will receive different trainings regrading endurance/balance/resistance,/coordination at home
Study NCT06321341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vespireit
Description: Buspirone
Study NCT06321341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arlevert
Description: Dimenhydrinate + Cinnarizine
Study NCT06035497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986369
Description: Specified dose on specified days
Study NCT05100147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine closure during Cesarean section
Description: The uterotomy is sutured after the delivery of the fetus and the placenta with an appropriate delayed absorbable suture (number 1 polyglactin 910)
Study NCT04932798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Resting ECG (if first visit is done on site only)
Description: The standard 12-lead electrocardiogram is a representation of the heart's electrical activity recorded from electrodes on the body surface.~This test requires around 15 minutes of the participant's time.
Study NCT04932798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour ambulatory electrocardiographic monitoring (Holter) (if first visit done on site only)
Description: The Holter monitor is a type of portable electrocardiogram (ECG) worn continuously for 24 hours.
Study NCT04932798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3-month AF detection monitoring using the Apple Watch
Description: Patients with irregular heart rates will be notified by the Apple Watch and instructed to confirm the rhythm by using the integrated ECG recording system. This simply requires touching the watch with a finger from the opposite hand and provides a 30 seconds one-lead ECG recording of diagnostic quality. These tracing will be transferred to the study team for analysis using a dedicated email.
Study NCT05281640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Dysregulation intervention
Description: See relevant study arm for description
Study NCT05281640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Self Concept intervention
Description: See relevant study arm for description
Study NCT05281640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disturbed Relationships intervention
Description: See relevant study arm for description
Study NCT06326918 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Duodenal mucosal brushing
Description: Duodenal mucosal brushing will be performed at duodenal bulb.
Study NCT06326918 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Duodenal mucosal biopsy
Description: Duodenal mucosal biopsy will be performed at duodenal bulb.
Study NCT06386549 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: tele-rehabilitation
Description: Using the social networking tool WeChat, families of children with burns are educated and trained through texts, photos, voice messages, and live videos, twice a week for a total of 12 weeks
Study NCT06386549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tele-rehabilitation
Description: Using the social networking tool WeChat, families of children with burns are educated and trained through texts, photos, voice messages, and live videos, twice a week for a total of 12 weeks
Study NCT04802785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Citicoline 500 mg (Vitaae®) per os
Study NCT04802785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytochrome C6
Description: Cytochrome10 mg per os
Study NCT04802785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride Oral Product
Description: Sodium Chloride (NaCl) 2.6 g. per os
Study NCT04802785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Chloride Oral Product
Description: Potassium Chloride 1.5 g per os
Study NCT04802785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Citrate Oral Product
Description: Sodium Citrate 2.90 g per os
Study NCT04802785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose Oral Tablet, Chewable
Description: Dextrose 13.5 g per os
Study NCT04802785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone Oral Product
Description: Domperidone 1 tablet per os
Study NCT04802785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: 3-4 capsules per os
Study NCT04802785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid 150 mg per os
Study NCT04802785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide
Description: magnesium hydroxide 30 mg per os
Study NCT04802785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Formula
Description: 1 capsule per os.
Study NCT04802785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 5 mg
Description: Melatonin 5 mg per os.
Study NCT05224648 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOF scan train of four ratio monitoring
Description: Device : TOF Scan For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
Study NCT05224648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITF device tetanus stimulation monitoring
Description: Device ITF For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
Study NCT05236595 — intervention group
Intervention type: OTHER
Intervention: Individualized drug matching per genetic disease
Description: Patient phenotype and samples will be evaluated for individualized therapeutic drug development
Study NCT05415709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT05415709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT05415709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT06468917 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1st day removal of abdominal drain
Description: once POPF is excluded in middle-low risk pancreatic resection, abdominal drains can be removed
Study NCT04763408 — intervention group
Intervention type: DRUG
Intervention: Lenvatinib
Description: Oral capsules.
Study NCT04763408 — intervention group
Intervention type: DRUG
Intervention: Sorafenib
Description: Oral tablets.
Study NCT05540600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg
Description: Patients will have the dose of one tablet of 0.25mg per day
Study NCT05540600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Patients will have the dose of bisoprolol 2.5 mg or 5 mg twice a day based on the arterial pressure at randomization
Study NCT04666129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: (Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day.~(Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day.
Study NCT04666129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone acetate (1000 mg \[2 x 500-mg tablets\]) or fine-particle abiraterone acetate (500 mg \[4 x 125-mg tablets\]) will be administered orally once daily.
Study NCT04666129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: (Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily.~(Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required.
Study NCT04666129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: For participants with mCRPC taking fine-particle abiraterone acetate, methylprednisolone 4 mg will be administered orally twice daily.
Study NCT04666129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide 240 mg (4 x 60-mg tablets) will be administered orally once daily.
Study NCT04666129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 dose will be administered every 3 weeks as a 1-hour intravenous infusion.
Study NCT05415709 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoreductive Surgery
Description: Undergo CRS
Study NCT05415709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery
Description: Undergo CRS
Study NCT05415709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: Undergo HIPEC
Study NCT05415709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT05415709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV